For Research Use Only

# CPI203

www.ptgcn.com

## Catalog Number: CM19253

### 产品信息

**Catalog Number:**
CM19253

**CAS号:**
202591-23-9

**分子式:**
$C_{19}H_{18}ClN_5OS$

**主要靶点:**
Epigenetic Reader Domain

**主要通路:**
表观遗传

**分子量:**
399.9

**溶解度:**
DMSO:200 mM



### 靶点活性

BET bromodomain:37 nM

### 体外活性

CPI203 inhibits BRD4 in vitro and in cells, while does not affect BRD4 kinase activity in vitro. [1] CPI203 exerts a cytostatic effect in all the 9 MCL cell lines analyzed with GI50 ranging from 0.06 to 0.71 μM, with low cytotoxicity in normal PBMCs from healthy donors. Furthermore, lenalidomide and CPI203, by targeting IRF4 and MYC, efficiently activates the cell death program in MCL cells resistant to bortezomib. [2]

### 细胞实验

MCL primary cells and cell lines are incubated as indicated with lenalidomide and/or CPI203. MTT is added for 2-6 additional hours before spectrophotometric measurement. Each measurement is made in triplicate. Values are represented using untreated control cells. The GI50 is calculated as the concentration that produced 50 % growth inhibition. Combination indexes (CIs) are calculated by using the Calcusyn software version 2.0. The interaction between two drugs is considered synergistic when CI <1. (Only for Reference)

### 描述

CPI-203 is an effective BET bromodomain inhibitor (IC50: 37 nM for BRD4).

### 储存

Powder: -20°C for 3 years | In solvent: -80°C for 2 years